ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / PODD / earnings
GMED (72) BAX (51) PEN (57) SOLV (45) ⌘ Pro Terminal →

Insulet Corporation (PODD) Next Earnings Date & Expected ±6.2% Move

$149.68 -1.85% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $149.54

Insulet Corporation (PODD) earns a Roarable Rating of B (Buy) with 73/100 RQD Confidence. High-quality cash engine (72% profit margin, 20% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 73/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.1% avg 90D alpha vs SPY • 69.0% hit rate) →
ROARABLE B • BUY Cap $10.58B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PODD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PODD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Insulet Corporation (NASDAQ: PODD) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 73/100 at a spot price of $149.68 (-1.85% 1D, market cap $10.58B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, PODD ranks #57 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PODD compare to GMED and BAX in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), PODD carries a Roarable B (73/100 RQD), trailing P/E of 42.8x, gross margin of 71.6%, and ROIC of 20.4%. By comparison, GMED (Globus Medical Inc.) holds a B grade (72/100 RQD, P/E 20.7x, ROIC 8.7%, cap $11.13B) and BAX (Baxter International Inc.) posts a D grade (51/100 RQD, P/E N/A, ROIC -2.4%, cap $12.15B). Among the 5-stock peer group, SOLV leads on earnings multiple (9.1x) while PODD leads on capital efficiency (20.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PODD?
▼

Per PODD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001145197), Insulet Corporation generated $2.71B in revenue (+30.7% YoY), $247.1M in net income, and $377.7M in free cash flow against $3.19B in total assets and $753.8M in total debt. Key quantitative strengths: Strong cash generator (72% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $149.55 (-0.09%)🧬 Cannibal Buyback (-2.36% YoY Shares)⚙️ Cash Engine: 19/20 (A+) • 13.9% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 73/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.1% avg 90D alpha vs SPY • 69.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B
025507510073
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B+ · Rk C+
Cash (19)Whales (11)SEC (18)Macro (9)CEO (16)
Each axis scored 0–20
12M PRICE TARGET CONE+6.7% Base Target
$373 Bull$160 Base$123 Bear
📬 FREE PODD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PODD)Realized 20D OHLCV Swing Band: ±6.2%
Deterministic 5-Pillar Attribution (73/100 Composite)
🔍 WHY PODD SCORES 73/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+19/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 13.9% FCF Margin ($377.7M FCF) & 71.6% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (25% of score)

Altman Z-Score 5.72 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▼ #1 Drag / Risk Factor: Macro Regime Fit9/20 pts (-11 pt drag)

Macro rate sensitivity & RSI-14 (66) create a -11 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
65
Grade C+$138.13+3.3% Next Q
Q2 (-2Q)
68
Grade B-$142.64+5% Next Q
Q3 (-1Q)
70
Grade B$149.83-0.1% Next Q
Current
73
Grade B$149.68+7.1% Hist 90D α
Trajectory: C+ (65) → B (73)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the PODD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 73/100 (B) score, PODD faces multiple-compression risk if 42.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Priced at 43x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($141.14) or 200D SMA ($177.45) invalidates the momentum regime and cuts Target Base ($159.78) toward Bear Floor ($122.74).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PODD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PODD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 73%NO 27%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±6.2% Swing Band

±$9.28 Expected Swing
$140.40 (-6.2%)Spot $149.68$158.96 (+6.2%)
MODEL EARNINGS SETUP GAUGE

PODD Quantitative Pre-Earnings Setup: 73/100

Trailing EPS: $3.56 • YoY Revenue Growth: 30.7%

Model Bullish Setup (73/100)Model Risk Weight (27/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$2.71B$247.1M$377.7M71.6%
FY 20242024-12-31$2.07B$418.3M$305.3M69.8%
FY 20232023-12-31$1.70B$206.3M$69.3M71.6%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating PODD & AI Leaders Without Chasing Tops

  • ✓Institutional whale strikes & implied earnings move audit on PODD
  • ✓How disciplined traders manage risk using pre-published trigger & invalidation levels
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PODD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -12.67%▲ ASCENDING TRIANGLE
2026-11-02O $148.9H $152.5L $148.9C $149.7VOL 1.30M
RES: $154.9SUP: $128.9SMA50: $141.1SMA200: $177.5
$292.3$247.4$202.4$157.4$112.4RES $154.9SUP $128.9$149.72026-05-042026-06-172026-08-042026-09-182026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PODD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PODD Butterfly Map → + Track PODD →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
32.2%/yr Implied 5Y Growth

vs. +30.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PODD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PODD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PODD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PODD)

Health Care Rank #57 of 1016 ⚔️ GMED vs PODD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PODD vs. GMED, BAX, PEN, SOLV)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Insulet Corporation (PODD) ranks #57 by composite RQD confidence (73/100, grade B) and #106 by equity capitalization ($10.58B). Within this direct 5-issuer industry benchmark cohort, SOLV leads on earnings valuation at 9.1x trailing P/E, while PODD leads on capital efficiency and profitability with 20.4% ROIC and 71.6% gross margin. PODD currently leads its immediate peer cohort in composite quantitative strength at 73/100 (B).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PODD ACTIVE
Insulet Corporation
B 73/100 42.8x 71.6% 20.4% -1.85% $10.58B Benchmark Subject
GMED
Globus Medical Inc.
B 72/100 20.7x 67.4% 8.7% -5.86% $11.13B /gmed-vs-podd →
BAX
Baxter International Inc.
D 51/100 — 30.1% -2.4% -2.13% $12.15B /bax-vs-podd →
PEN
Penumbra Inc.
D+ 57/100 71.4x 67.1% 10.6% -0.94% $12.68B /pen-vs-podd →
SOLV
Solventum Corporation
D 45/100 9.1x 53.5% 18.7% -2.67% $14.22B /solv-vs-podd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001145197

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Insulet Corporation (PODD) reported GAAP revenue of $2.71B (+30.7% vs. FY2024 revenue of $2.07B , and +59.6% cumulative change since FY2023) , GAAP net income of $247.1M, operating cash flow of $569.3M, and free cash flow of $377.7M (+23.7% YoY). On the balance sheet, PODD closed FY2025 with $3.19B in total assets against $753.8M in total debt (Altman Z-Score: 5.72, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $2.71B $247.1M $569.3M $377.7M $3.19B $753.8M
FY2024 (FY) 2024-12-31 $2.07B $418.3M $430.2M $305.3M $3.09B $844.2M
FY2023 (FY) 2023-12-31 $1.70B $206.3M $145.7M $69.3M $5.82B $1.36B

3. PODD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PODD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Insulet Corporation (NASDAQ: PODD) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 73/100 at a spot price of $149.68 (-1.85% 1D, market cap $10.58B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, PODD ranks #57 in composite RQD confidence.

How does PODD compare to GMED and BAX in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), PODD carries a Roarable B (73/100 RQD), trailing P/E of 42.8x, gross margin of 71.6%, and ROIC of 20.4%. By comparison, GMED (Globus Medical Inc.) holds a B grade (72/100 RQD, P/E 20.7x, ROIC 8.7%, cap $11.13B) and BAX (Baxter International Inc.) posts a D grade (51/100 RQD, P/E N/A, ROIC -2.4%, cap $12.15B). Among the 5-stock peer group, SOLV leads on earnings multiple (9.1x) while PODD leads on capital efficiency (20.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PODD?

Per PODD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001145197), Insulet Corporation generated $2.71B in revenue (+30.7% YoY), $247.1M in net income, and $377.7M in free cash flow against $3.19B in total assets and $753.8M in total debt. Key quantitative strengths: Strong cash generator (72% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PODD trading relative to its 50-day, 200-day, and 52-week technical levels?

PODD last traded at $149.68 (-1.85% on volume of 1,090,433 shares), positioning the stock +6.05% above its 50-day simple moving average ($141.14) and -15.65% below its 200-day simple moving average ($177.45). Across its 52-week range of $126.40 to $354.88, PODD sits at the 10.2% percentile with a 14-day RSI of 66.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±6.2% ($140.40 to $158.96).

PODD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is PODD's next earnings date?

Based on SEC filing cadence, Insulet Corporation (PODD)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is PODD stock expected to move on earnings?

Volatility modeling currently projects a ±6.2% event move for PODD, spanning a range between $140.4 and $158.96.

Direct Sub-Reports: PODD RQD Cockpit PODD 12M Forecast PODD Earnings & Move PODD Dividends & DRIP PODD Insiders & 13F PODD Whale Options PODD Profit Sankey PODD News & Why
ROARABLE RATING BRIEF • RQD 73/100 (B) ✓ STAGE-C NUMBER FIREWALL VERIFIED

PODD — Insulet Corporation: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:16:22Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, PODD scores 73 out of 100, graded B and labeled "Roarable Buy — Good Risk/Reward." The five pillars are: Fundamental Cash Engine 19/20 (ROIC 20.4%; FCF yield 3.57%), Whale 13F Flow 11/20 (institutional accumulation and options positioning), Insider Conviction 16/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 9/20 (Beta 0.99; sector sensitivity), and Forensic Balance Sheet 18/20 (Altman Z 5.72; Piotroski F 8/9; Debt/Equity 0.46).

The strongest pillar is the cash engine, which indicates the rating's fundamental case rests mainly on returns on invested capital and free-cash-flow generation rather than on valuation. The forensic balance-sheet pillar is also strong. The weakest pillar is macro regime fit, where the near-market beta suggests the stock tracks broader market movement rather than diverging from it. Whale flow is moderate. Upside drivers in this framework are continued cash generation and balance-sheet strength; valuation tradeoffs are visible in the elevated trailing P/E relative to the forward P/E, and the 3.57% FCF yield should be weighed against those multiples. This is an analytical summary of the rating's components, not personalized financial advice.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
152.5$10.58B42.83617.13.560%0.99$126.4 - $354.8820.4%

Business

Insulet Corporation is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry, per the company profile. Not available in source data for specific products, customers, or revenue-generation detail. The source data reports gross margin of 71.6%, operating margin of 17.5%, and net margin of 9.1% per the market data section.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$2708.1M$473.8M$247.1MN/A$377.7MN/A$753.8M
FY 2024$2071.6M$308.9M$418.3MN/A$305.3MN/A$844.2M
FY 2023$1697.1M$220.1M$206.3MN/A$69.3MN/A$1361.2M

Reported revenue rose across the three periods, from $1697.1M in FY 2023 to $2708.1M in FY 2025, and debt declined from $1361.2M to $753.8M over the same span. Net income was $418.3M in FY 2024 and $247.1M in FY 2025. Per the market data, ROIC is 20.4% and net margin is 9.1%. Per the Roarable RQD forensic pillar, the Altman Z-Score is 5.72, the Piotroski F-Score is 8/9, and Debt/Equity is 0.46, which together describe a balance sheet the source data characterizes as strong. Cash balances are not available in source data.

Open Questions

  • What are the reported cash balances, since the financials section lists cash as N/A for every period?
  • What are the reported EPS figures, since the financials section lists EPS as N/A for every period?
  • What is the analyst consensus rating and price target, given that analyst data is absent?
  • What is the reported supply-chain exposure, given the butterfly graph shows no links?
  • How do the 52-week high and low ($354.88 and $126.4) relate to the drivers behind the current price of $152.5?

PODD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Insulet Corporation (PODD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PODD Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PODD Bull vs. Bear Conversation Board — What's Your Call at $149.68?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PODD 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PODD:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH 🎯 Target: $179.95 (+18.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is PODD (B • RQD 73/100) a Buy at $152.50?

Welcome to the PODD (Insulet Corporation) Roar Pit. Current RQD Composite is 73/100 (Roarable Buy — Good Risk/Reward) in Medical/Dental Instruments. Bulls point to capital efficiency (20.4% ROIC), while bears focus on valuation multiple compression (42.8x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $125.05 (-18.0%)
Spot @ $152.50

Pump the brakes on PODD — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on PODD, but look at what you are paying: 42.8x trailing P/E with 71.6% gross margins. Unless Insulet Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $176.90 (+16.0%)
Spot @ $152.50

PODD cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on PODD, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $152.50 (52-wk range $126.40 - $354.88), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%